Phase 2 Immune Thrombocytopenia Clinical Trials
31 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 31 trials
Recruiting
Phase 2Phase 3
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
Immune Thrombocytopenic PurpuraITPITP - Immune Thrombocytopenia+1 more
argenx24 enrolled8 locationsNCT07194850
Recruiting
Phase 1Phase 2
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Immune Thrombocytopenia (ITP)
Eli Lilly and Company58 enrolled45 locationsNCT06721013
Recruiting
Phase 2
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Immune Thrombocytopenia
Incyte Corporation56 enrolled40 locationsNCT07104565
Recruiting
Phase 1Phase 2
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
ITPImmune Thrombocytopenia (ITP)Monoclonal+2 more
Climb Bio, Inc.24 enrolled20 locationsNCT07043946
Recruiting
Phase 2
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China160 enrolled1 locationNCT07234019
Recruiting
Phase 2
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China160 enrolled1 locationNCT07297563
Recruiting
Phase 2
The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia
Relapsed/Refractory Immune Thrombocytopenia
Seoul National University Hospital29 enrolled4 locationsNCT05599880
Recruiting
Phase 2
A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)
Immune Thrombocytopenia (ITP)
Dizal Pharmaceuticals60 enrolled1 locationNCT07294365
Recruiting
Phase 2
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China122 enrolled1 locationNCT07362238
Recruiting
Phase 2
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT07362199
Recruiting
Phase 1Phase 2
A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
Primary Immune Thrombocytopenia (ITP)
Jiangsu BioJeTay Biotechnology Co., Ltd.56 enrolled7 locationsNCT06929299
Recruiting
Phase 1Phase 2
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
Autoimmune Hemolytic AnemiaEvans SyndromeAutoimmune Cytopenia+1 more
Keymed Biosciences Co.Ltd158 enrolled3 locationsNCT07175493
Recruiting
Phase 2
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China60 enrolled1 locationNCT06168851
Recruiting
Phase 2
The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)
Immune Thrombocytopenia (ITP)
Peking University People's Hospital132 enrolled3 locationsNCT07065968
Recruiting
Phase 1Phase 2
A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT06776510
Recruiting
Phase 2
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China30 enrolled1 locationNCT06838962
Recruiting
Phase 2
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
Immune Thrombocytopenia (ITP)
Nuvig Therapeutics, Inc.10 enrolled1 locationNCT07095127
Recruiting
Phase 2
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China30 enrolled1 locationNCT07063199
Recruiting
Phase 1Phase 2
A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
Chronic Immune Thrombocytopenia
CASI Pharmaceuticals, Inc.75 enrolled6 locationsNCT07017725
Recruiting
Phase 2
Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial
Primary Immune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital, China129 enrolled1 locationNCT06992128